Market Cap$84.97B
P/E26.14x
PEG Ratio1.55
Div yield6.25%
Beta1.01
MMM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-1.91%
Price vs S&P 500 (4W)1.19%
PEG Ratio1.55
VGM Score50.21
P/E Ratio (Annual)26.14x
Indicated Dividend Yield (Annual)6.25%
MMM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.25 | $2.40 | +6.84%(+$0.15) | |
| Q1 2026 | $1.98 | $2.14 | +7.88%(+$0.16) | |
| Q4 2025 | $1.80 | $1.83 | +1.79%(+$0.03) | |
| Q3 2025 | $2.07 | $2.19 | +5.60%(+$0.12) | |
| Q2 2025 | $2.01 | $2.16 | +7.37%(+$0.15) |
MMM Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.74
3.61
3.65
3.58
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About 3M Company
3M is a multinational industrial conglomerate with a diversified product portfolio across safety and industrial solutions (44% of revenue), transportation and electronics (36%), and consumer goods (20%). The company leverages proprietary technologies and strong R&D capabilities to develop innovative products across thousands of offerings worldwide. With operations spanning the globe, 3M generates nearly half its revenue internationally. In 2024, the company separated its healthcare business into an independent entity, Solventum, to focus on its core industrial and consumer segments.